Jushi Biotech rose more than 5% as Morgan Stanley said it could achieve a GAGR of about 20% in the next two years.

Genimous Biotech (02367) rose over 5%, as of the time of writing, up 5.13% to HK$42, with a trading volume of HK$123 million.

Morgan Stanley released a research report, stating that the Company aims for a 30% to 35% growth in sales in the second half of the year, and the Company said that the growth in the third quarter was largely in line with the plan, which is positive news, especially as the Company did not make much promotion in the off-season. The bank believes that the management's guidance of a 35% profit growth this year and a 20% revenue compound annual growth rate (CAGR) from 2024 to 2026 is achievable, and believes that the stock is currently trading at a low valuation with a 16 times forecast price-to-earnings ratio for 2025.

Western Securities said that the traffic of institutional terminals began to rebound after the Mid-Autumn Festival, and the traditional traffic of medical aesthetics terminals will peak from the National Day holiday to the Spring Festival. Most medical aesthetics institutions will start a series of marketing activities from September and October, and the traffic is expected to gradually rebound in mid-October, driving the growth of terminal and upstream revenue. In addition, several companies launched new products in August and September to prepare for Double 11, and all new products are actively preheating, waiting for the promotion node of Double 11.